Bioceres Crop Solutions Corp. · NASDAQ:BIOX
Bioceres Crop Solutions — Q4 2025 Earnings Presentation
16 slides from Bioceres Crop Solutions's earnings presentation, Sep 9, 2025
Slide 1: Fiscal Fourth Quarter & Full-Year
Fiscal Fourth Quarter & Full-Year September / 2025
Slide 2: Disclaimer
BIOCERES CROP SOLUTIONS Disclaimer Industry and Market Data Unless otherwise noted, the forecasted industry and market data contained in the assumptions for the projections are based upon the Company’s management estimates For example, other companies may calculate non-IFRS measures differently, or
Slide 3: FY25 Performance
BIOCERES CROP SOLUTIONS FY25 Performance After a strong multi-year growth Revenue Evolution ($ Million) trajectory, FY25 was impacted by severe challenges: +11% +28% -28% Extraordinary sales in FY24 465 420 Weak on farm economics +58% +20% 328 335 +8% Deterioration in financing conditions 207 in the
Slide 4: Revenue by Segment
BIOCERES CROP SOLUTIONS 4Q24 4Q25 Revenue ($ Million) 37.5 24.7 by Segment -34% 124.0 74.7 40% Quarterly and full-year revenues were impacted by weaker demand in Argentina and reduced HB4-related sales. 33.3 53.2 8.4 41.7 -75% -22% International markets remained resilient, supported mainly by bio-pr
Slide 5: 4Q25 Gross Profit by Segment
BIOCERES CROP SOLUTIONS 4Q25 Gross Profit by Segment 4Q25 4Q25 Gross Profit Bridge 4Q25 Contraction ($ Million) 0.6 47.4 (2.2) Gross profit decline reflects same dynamics (10.6) observed in revenues. (9.3) Gross Profit Crop Nutrition and Seeds segments 25.2 25.2 responsible for majority of the reduc
Slide 6: FY25 Gross Profit by Segment
BIOCERES CROP SOLUTIONS FY25 Gross Profit by Segment FY25 FY25 Gross Profit Bridge FY25 Contraction ($ Million) 19.1 186.6 (11.5) The decline in gross profit reflects lower sales (31.9) across segments, including a $15.7 million year-over-year reduction from the Syngenta downpayment that carried a 1
Slide 7: 4Q25 Adjusted EBITDA
BIOCERES CROP SOLUTIONS 4Q25 Adjusted 4Q25 EBITDA1 ($ Million) 19.9 (22.7) Adjusted EBITDA1 decline mainly driven by lower gross profit and non-recurring impairments, which fully offset OPEX improvements from cost-control initiatives. (4.5) 5.7 (2.3) (5.0) Adj. EBITDA1 Impairment of Opex Other incom
Slide 8: FY25 Adjusted EBITDA
BIOCERES CROP SOLUTIONS FY25 Adjusted FY25 EBITDA1 ($ Million) 81.4 (15.7) As in the quarter, the decline in Adjusted (38.9) EBITDA was mainly driven by the sharp decrease in gross profit. Non-recurring impairments outweighed the OPEX efficiencies achieved through cost-control initiatives. 3.9 28.3
Slide 9: Cash Flow Performance
BIOCERES CROP SOLUTIONS Cash Flow Performance ($ Million) 4Q24 4Q25 Change FY24 FY25 Change Net cash flow generated by operating activities was higher YoY, despite decline in profitability. Net cash flows generated by operating activities 23.3 29.9 28% 41.7 53.0 27% Net cash consumption for both the
Slide 10: Balance Sheet & Cash Position
BIOCERES CROP SOLUTIONS Balance Sheet 3Q25 ($ Million) 4Q25 & Cash Position ($ Million) ($ Million) Net Debt Net Debt 4.13x 7.8x Adj. EBITDA1 Adj. EBITDA1 The Company entered into amendments to its note purchase agreements and outstanding notes during 4Q25. 217.4 220.8 Repayment of Unsecured Public
Slide 11: Financial Strategy
BIOCERES CROP SOLUTIONS Financial Strategy Debt Right-sizing refinancing of costs Amendment to notes extending maturities Debt rollover Reduce pace of Cash investment in generation Capex and R&D Continued to prioritize efficiencies in working capital management and cash generation FOURTH QUARTER 202
Slide 12: Looking Ahead
BIOCERES CROP SOLUTIONS Looking Ahead New seed business strategy, exiting Pivoting of Seed Business breeding and seed production activities to focus on trait development and partnerships for market access. Shift from Topline Growth to Profitability +40% Focus on Cash Generation Gross Margin Portfoli
Slide 13: Exhibits
Exhibits ee
Slide 14: Unaudited Consolidated Statement of Comprehensive Income
BIOCERES CROP SOLUTIONS Three-month Three-month Fiscal Year Fiscal Year period ended period ended ended ended Unaudited Revenues from contracts with customers Initial recognition and changes in the fair value of biological assets at the point 6/30/2025 74.4 6/30/2024 124.3 06/30/2025 333.3 06/30/202
Slide 15: Non-IFRS Financial Measures
BIOCERES CROP SOLUTIONS Non-IFRS Financial Measures Adjusted EBITDA The company defines adjusted EBITDA as net income/(loss) exclusive of • Other companies may calculate adjusted EBITDA and similarly titled financial income/(costs), income tax benefit/(expense), depreciation, measures differently, l
Slide 16: Contact Us: Investor Relations
Contact Us: Investor Relations Investorrelations@biocerescrops.com // Investors.biocerescrops.com
Bioceres Crop Solutions — Q4 2025 Earnings Presentation on 6ix